With effect 25 March 2019 the pricing approach of the Janus Henderson UK Property PAIF and the Janus Henderson UK Property PAIF Feeder Fund will be changing.
The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences Team, making it important for investors to focus on both the science and commercial potential of new medicines.
In this video update, Simon Hillenbrand, Head of UK Retail, summarises why the Janus Henderson UK Property PAIF and its Feeder Fund will change from being dual priced on a quoted-spread basis to being dual priced on a full-spread basis, with effect from 25 March 2019. Meanwhile, Ainslie McLennan, Co-Manager of the Janus Henderson UK Property PAIF, provides an update on portfolio positioning and her outlook for the asset class.
Portfolio Managers Marc Pinto and Jeremiah Buckley look at the prospects for domestic U.S. equities, following a turbulent 2018.
Learn the three critical elements to enhance your negotiation skills in an exclusive interview hosted by Dr. John Evans, Jr. with negotiations expert Professor G. Richard Shell.
Daniel Lyons is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors, a role he has held since 2018.
Perkins Chief Investment Officer Greg Kolb shares his equity market insights.
Are you a “stressaholic”? Guest blogger Dr. Heidi Hanna provides insights on how you can better manage your stress rather than it managing you.
Charlie Awdry, China equities portfolio manager, gives a first-hand insight into the culture, company dynamics and consumer trends experienced during his recent research trip to China.
The Fed’s January senior loan officer survey provides further evidence of a deterioration in US economic prospects, signalling a tightening of loan supply and – more significantly – markedly weak credit demand.